BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, September 24, 2023
Home » Topics » Financings

Financings
Financings RSS Feed RSS

Layoff, shutdown illustration

Amid hard industry times, Histogen gives up as thinner Kinnate hangs on

Sep. 19, 2023
By Randy Osborne
No Comments
Having cast around for other routes, Histogen Inc. is throwing in the towel, its board having adopted a shutdown plan that includes the distribution of remaining cash to stockholders after a wind-down of operations. One of the company’s West Coast peers, Kinnate Biopharma Inc., had news, too. The firm disclosed the layoff of 70% of its workforce, including all employees at the Shanghai-based subsidiary Kinnjiu Biopharma Inc., leaving the outfit with 28 full timers.
Read More
Gold dollar sign inside gold cog

Pass the (molecular) glue: Magnet school teaches new way with $50M series A

Sep. 19, 2023
By Randy Osborne
No Comments
Magnet Biomedicine Inc. emerged from stealth mode and pulled down a $50 million series A round co-led by founding investor Newpath Partners alongside Arch Venture Partners. The firm is advancing molecular glue discovery by way of rational selection and design, looking past known protein-protein interactions and what Magnet calls “tangential” degradation approaches to analyze the broader protein landscape and ultimately pair targets with rationally chosen presenters in the tissue where the disease manifests.
Read More

Briya raises $11.5M to expand health care data exchange platform

Sep. 19, 2023
By Shani Alexander
No Comments

Israeli startup Briya Ltd. raised $11.5 million in series A financing which will support the expansion of its health care data exchange platform across Europe and the U.S. The round was led by Team8, and included existing investors Insight Partners, and Amiti Ventures, and was joined by the George Kaiser Family Foundation.


Read More

Financings for Sept. 19, 2023

Sep. 19, 2023
No Comments
Med-tech firms raising money in public or private financings, including: Biolase, Elutia, Virtual Incision.
Read More

Financings for Sept. 19, 2023

Sep. 19, 2023
No Comments
Biopharmas raising money in public or private financings, including: Atamyo, Bioloomics, Biora, Clearmind, Eloxx, Everimmune, Hyku, Recode.
Read More

Financings for Sept. 19, 2023

Sep. 19, 2023
No Comments
Biopharmas in Asia-Pacific raising money in public or private financings: Brim, Recce.
Read More
Stimvias URIS neuromodulation system

Stimvia raises funds for Uris system to manage overactive bladder

Sep. 18, 2023
By Shani Alexander
No Comments
Stimvia s.r.o. (previously Tesla Medical s.r.o.) is in the process of securing $10 million in investment in a series A financing round that will allow the company to conduct a pivotal clinical study addressing overactive bladder, using Uris, its neuromodulation system, CEO Lukas Doskocil told BioWorld.
Read More

Financings for Sept. 18, 2023

Sep. 18, 2023
No Comments
Med-tech firms raising money in public or private financings, including: Cardiacare, Field Medical.
Read More

Financings for Sept. 18, 2023

Sep. 18, 2023
No Comments
Biopharmas raising money in public or private financings, including: Aboleris, Acesis, Broken, Oxurion, Titan.
Read More
Going public ticker

Two IPOs launch in a tepid market

Sep. 15, 2023
By Lee Landenberger
No Comments
In the daunting shadow of previous years’ numbers, two companies jumped into this year’s relatively tepid IPO market. Rayzebio Inc. priced its upsized $311 million IPO of 17.2 million shares at $18 each. Gross proceeds of about $290.1 million are expected by the radiopharmaceutical cancer therapy developer. On Sept. 15, shares (NASDAQ:RYZB) closed up 33.3% at $24 each. Also, Neumora Therapeutics Inc. priced its IPO of 14.7 million shares at $17 each, looking for gross proceeds of about $250 million. The company, which is developing seven products targeting brain diseases, saw shares (NASDAQ:NMRA) close 4.4% downward at $16.25 on Sept. 15.
Read More
Previous 1 2 3 4 5 6 7 8 9 … 420 421 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Sept. 22, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for September 22, 2023.
  • Hands holding torn contract

    Quite a fix: Orthofix sacks three top execs

    BioWorld MedTech
    Orthofix Medical Inc. terminated its CEO, chief financial officer and chief legal officer in a move that plunged the stock from $18.63 at Monday’s close to $13.01...
  • Illustration of Alzheimer’s in the brain.

    Study identifies cause of death for Alzheimer’s neurons

    BioWorld
    By creating a new mouse model of Alzheimer’s disease that better recapitulated how the disease plays out in humans, investigators at KU Leuven have gained new...
  • New NLRP3 inflammasome inhibitors named in PTC Therapeutics patent

    BioWorld Science
    PTC Therapeutics Inc. has patented new NLRP3 inflammasome inhibitors reported to be useful...
BioFuture ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing